Monday, February 11, 2013- Can This Celgene Drug Defy the Patent Cliff?at Motley Fool (Mon, Feb 11)
- Amgen, UCB halt testing of fracture-healing drugAP (Mon, Feb 11)
- [video] Buy Market Dips, Not Bondsat TheStreet (Mon, Feb 11)
- 1 Powerhouse Drug in Celgene's Pipelineat Motley Fool (Mon, Feb 11)
- Why Investors Should Be Cautious Of 'Artificial' Dividend Growthat Seeking Alpha (Mon, Feb 11)
- Backed By Large Pharma And Key Investors, Pharmacyclics Is Set To Climb Higherat Seeking Alpha (Mon, Feb 11)
- Has Elan Become the Perfect Stock?at Motley Fool (Mon, Feb 11)
- HIV/AIDS and Gilead Sciencesat Motley Fool (Mon, Feb 11)
- More Good News for Celgeneat Motley Fool (Mon, Feb 11)
Sunday, February 10, 2013 Friday, February 8, 2013- Colgate, Avon Decline as Venezuela Devalues Its Currencyat Bloomberg (Fri, Feb 8)
- J&J President Visited Hip Surgeon Pre-Recall, Jury Toldat Bloomberg (Fri, Feb 8)
- Can Johnson & Johnson Cash In on Stelara?at Motley Fool (Fri, Feb 8)
- [video] Who's Left to Buy Stocks?at CNBC (Fri, Feb 8)
- Easy, Peasy, Just "Pick Winners"at Motley Fool (Fri, Feb 8)
- Failure Of Nobori Trial Raises Questions For Dissolving-Polymer Stent Rivalsat Seeking Alpha (Fri, Feb 8)
- Still Revving Up With Revlimidat Motley Fool (Fri, Feb 8)
- HP Updates Supplier Guidelines and 2 Dow Movers Turning Headsat Wall St. Cheat Sheet (Fri, Feb 8)
- A Warning to Beginning Investors: Ease Yourself Into This Marketat Motley Fool (Fri, Feb 8)
- To All You Cash-Laden Companies: Where are the Stock Buybacks?YCharts (Fri, Feb 8)
- The All-Defensive Team: 20 Low-Beta Dividend Stocks For Your Retirement Portfolio (Part 1)at Seeking Alpha (Fri, Feb 8)
- Serial Acquirers Can Be Good Investmentsat Motley Fool (Fri, Feb 8)
Add JNJ News to My Yahoo!   | |
|
1.35%